MGC Pharmaceuticals, Ltd.

mgcpharma.com.au

MGC Pharmaceuticals Ltd. is an Australian Company publicly listed on the ASX (ASX:MXC) founded in early 2015 by leading Israeli medical cannabis industry executives. The goal was establishing a global cannabinoid (CBD) and medical cannabis business utilizing their intellectual property, expertise and contacts, with a focus on the CBD market in Europe and Australia. MGC is operates globally with an agenda of adding value to the whole product chain, from growing and breeding unique strains to developing medicine delivery systems. With the Medical Cannabis industry, and particularly the CBD subsection of this industry booming globally, now is a time where making correct choices in partnerships and associations becomes most crucial.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

news image

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More

Business Insights

KUBOTA VISION ANNOUNCES COLLABORATION AGREEMENT WITH LEADING DIABETES CENTER

PBOS | September 30, 2022

news image

Kubota Vision Inc. a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. announced today that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite in-home optical coherence tomography device. Joslin Diabetes Center is conducting two clinical studies to evaluate the ability of PBOS to identify cases of diabetic macular ed...

Read More

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

news image

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More

Business Insights, PHARMA TECH

EU APPROVES ZYNLONTA FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

ADC Therapeutics | January 03, 2023

news image

Sobi® and ADC Therapeutics SA informed that Zynlonta® (loncastuximab tesirine) has recently received conditional marketing authorization from the European Commission (EC) for the treatment of diffuse large B-cell lymphoma ((DLBCL) that has relapsed or become resistant. The approval comes after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a favorable opinion in September. Sobi has said that it wants to give Zynlonta, a new treatm...

Read More
news image

Business Insights

LIFESPIN LAUNCHES COMMERCIAL ACCESS TO ITS METABOLIC PROFILER SOFTWARE AND DATABASE FOR PHARMA AND BIOBANK SERVICES

Lifespin | September 16, 2022

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced that it has launched a new commercial service that, for the first time, will provide the pharmaceutical and biobanking industry with access to Lifespin’s proprietary metabolic database, along with its advanced interpretive software to assist in various phases of drug research, development, and manufacturing. Immediate applications of Lifespin’s commercial services will include quality c...

Read More
news image

Business Insights

KUBOTA VISION ANNOUNCES COLLABORATION AGREEMENT WITH LEADING DIABETES CENTER

PBOS | September 30, 2022

Kubota Vision Inc. a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. announced today that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite in-home optical coherence tomography device. Joslin Diabetes Center is conducting two clinical studies to evaluate the ability of PBOS to identify cases of diabetic macular ed...

Read More
news image

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More
news image

Business Insights, PHARMA TECH

EU APPROVES ZYNLONTA FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

ADC Therapeutics | January 03, 2023

Sobi® and ADC Therapeutics SA informed that Zynlonta® (loncastuximab tesirine) has recently received conditional marketing authorization from the European Commission (EC) for the treatment of diffuse large B-cell lymphoma ((DLBCL) that has relapsed or become resistant. The approval comes after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a favorable opinion in September. Sobi has said that it wants to give Zynlonta, a new treatm...

Read More